Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

RPE65

Gene therapy (AAV vector) · Gene replacement · developed by MeiraGTx UK II

Phase 1/2 Most advanced trial (none active)
MGTX Developer
1 Registered trials

What is RPE65?

AAV RPE65 is an adeno-associated viral vector gene therapy that delivers the RPE65 gene. It is being studied in Leber congenital amaurosis, an inherited retinal disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy (AAV vector)
Mechanism
Gene replacement
Therapy area
Ophthalmology
Developer
MeiraGTx UK II Ltd (MGTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
CH2LY7Q64L

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02781480 Phase 1/2 Leber Congenital Amaurosis Completed MGTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Leber Congenital Amaurosis

More from MeiraGTx UK II

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MGTX page.

Follow MGTX, the company behind RPE65

See MGTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.